semaglutide
Retatrutide vs Tirzepatide Which Outperforms Semaglutide
Retatrutide outperforms tirzepatide and semaglutide in MC4R-deficient obesity, delivering larger and more durable weight loss. In a 12-month prospective cohort, patients on 10 mg weekly retatrutide lost 18% of baseline weight and kept 83% of that loss at month 12, exceeding tirzepatide’s 15% loss and semaglutide’s 12%. Medical